News | Balloon Catheter | May 20, 2021

Boston Scientific Initiates First Coronary Drug-Coated Balloon Study in the U.S.

AGENT IDE will evaluate the AGENT DCB as potential therapy for patients with in-stent restenosis, may offer alternative to repeated stenting or radiation therapy

AGENT IDE will evaluate the AGENT DCB as potential therapy for patients with in-stent restenosis, may offer alternative to repeated stenting or radiation therapy

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated Balloon (DCB), the first clinical trial in the U.S. to evaluate the safety and effectiveness of a DCB in patients with coronary in-stent restenosis (ISR).

Coronary stenting, in which a stent is inserted into a coronary artery to restore blood flow to the heart, continues to show a substantial improvement in symptoms and quality of life for patients with coronary artery disease. However, in some patients, the stented section of the artery may become obstructed or narrowed by scar tissue, leading to a condition known as ISR. Approximately 10% of percutaneous coronary interventions (PCIs) address this issue and current treatment approaches include the insertion and layering of additional stents, or radiation, both of which introduce potential safety risks for patients.

"While the possibility of ISR remains a challenge for cardiologists, the Agent DCB provides a potential new approach to re-opening the vessel and reducing the risk of ISR reoccurrence over time,” said Principal Investigator Robert W. Yeh, M.D., director of the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology at the Beth Israel Deaconess Medical Center, and associate professor of medicine at Harvard Medical School. “In this new study, we are evaluating a metal-free and radiation-free treatment that could become a safe and more effective long-term alternative for certain patients.”

The AGENT DCB is a percutaneous transluminal coronary angioplasty balloon that is coated with an anti-restenotic drug and delivered via a proprietary coating technology. The balloon is designed to open narrowed vessels and then transfer the drug to the vessel wall. This technology was granted Breakthrough Device designation by the U.S. Food and Drug Administration earlier this year, a status intended to provide patients more timely access to novel devices that may provide a substantial improvement over existing therapies. The AGENT IDE trial is designed to assess the safety and effectiveness of treating ISR with the Agent DCB.

The prospective, randomized trial will compare the Agent DCB to treatment with an uncoated balloon, commonly referred to as “plain old” balloon angioplasty (POBA), in patients with ISR in lesions up to 26 mm in length in a coronary artery 2.0 mm to 4.0 mm in diameter. The study will evaluate the 12-month target lesion failure rate, defined as myocardial infarction related to the target vessel, the need for a revascularization procedure or cardiac mortality. At least 480 patients will be enrolled in the study at 40 U.S. sites.

“We believe the Agent DCB could expand options for physicians managing in-stent restenosis, which can be difficult to treat and frequently reoccurs with conventional treatments,” said Ian Meredith, M.D., global chief medical officer, Boston Scientific. “We are pleased to be leading this study, which may bring this technology to a greater number of patients with coronary artery disease and address the unmet need for a reliable and sustained treatment for their ISR.”

The device has been approved in Europe since 2014 for patients with ISR and previously untreated small vessel coronary disease. The 2018 European Society of Cardiology and European Association for Cardio-Thoracic Surgery Guidelines on Myocardial Revascularization support the use of DCBs with a Class IA recommendation for patients with in-stent restenosis of drug-eluting stents or bare-metal stents.

For more information: www.bostonscientific.com

Find more drug-eluting balloon technology content

Related Content

Example of an angioplasty balloon catheter being expanded inside an artery to push atherosclerotic plaque and thrombus out of the way to reopen the vessel lumen to increase or reopen bloodflow. Balloon catheters are used to revascularize patients with heart attacks and to deploy stents to prop open the expended vessel.

Getty Images

Feature | Balloon Catheter | March 16, 2021 | By Dave Fornell, Editor
The first devices developed for interventional cardiology were...
A comparison showing angiography and optical coherence tomography (OCT) views of an undilated mid right coronary artery calcified lesion, post dilation with the Shockwave intravascular lithotripsy system, and the final result after stenting. The technology allows calcified lesions to be broken up without the need for vessel trauma caused by high pressure balloons or atherectomy. 

A comparison showing angiography and optical coherence tomography (OCT) views of an undilated mid right coronary artery calcified lesion, post dilation with the Shockwave intravascular lithotripsy system, and the final result after stenting. The technology allows calcified lesions to be broken up without the need for vessel trauma caused by high pressure balloons or atherectomy.

Feature | Balloon Catheter | February 17, 2021
February 17, 2021 — The U.S.
Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score Percutaneous Transluminal Angioplasty (PTA) Scoring Sheath platform for use in iliac, ilio-femoral, popliteal, infra-popliteal and renal arterial plus synthetic and/or native arteriovenous hemodialysis fistula. This is a new type of scoring balloon technology.
News | Balloon Catheter | June 04, 2020
June 4, 2020 — Transit Scientific announced the U.S.
NC Trek RX Coronary Dilatation Catheter is part of an FDA Class I recall because it may not defalte.
News | Balloon Catheter | February 24, 2020
February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters
Edwards Lifesciences Recalls IntraClude Intra-aortic Occlusion Device
News | Balloon Catheter | July 15, 2019
Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon rupture during...
Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports